On September 11, 2020 Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company reported a strategic partnership agreement with Hualan Genetic Engineering Co., Ltd (Hualan Genetic) to develop HBM’sHBM’s three proprietary innovative monoclonal and bispecific antibodies (Press release, Harbour BioMed, SEP 11, 2020, View Source [SID1234565054]).

Under the terms of the agreement, Hualan Genetic will be responsible for preclinical and process development in exchange for exclusive rights for the development, manufacturing, and commercialization of these innovative antibody drugs in Greater China (Mainland China, Hong Kong, Taiwan and Macau). HBM will retain the rights for advancing the clinical development and commercialization in rest of the world. Both parties will collaborate on clinical developments and drug manufacturing. HBM will receive an upfront payment of USD 8.75M and royalties based on sales in Greater China.

Using its proprietary H2L2 and HCAb fully human transgenic mouse platforms, HBM has developed a series of novel antibody candidates against oncology and immunological diseases. Many of these candidates have already progressed to preclinical and clinical stages. HBM has developed an immune cell engager platform HBICE, and one product of this collaboration with Hualan Genetic is HBICE bispecific antibody.

Hualan Genetic has been dedicated to R&D and the production of monoclonal antibodies, recombinant human coagulation factors, recombinant hormone drugs. To date, the company has 19 recombinant protein products under development and 7 monoclonal antibody products that received approval for the clinical trial, among which several are under Phase III clinical study. Hualan Genetic is a novel biopharmaceutical company specializing in R & D, production and sales with product indications covering a dozen major diseases, including breast cancer, melanoma, lung cancer, colorectal cancer,

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 11, 2020 The board of directors of AbbVie Inc. (NYSE: ABBV) reported a quarterly cash dividend of $1.18 per share (Press release, AbbVie, SEP 11, 2020, View Source [SID1234565001]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The cash dividend is payable November 16, 2020 to stockholders of record at the close of business on October 15, 2020.

Since the company’s inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

On September 11, 2020 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), reported that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 11:00 AM EDT (Press release, Regulus, SEP 11, 2020, View Source [SID1234565019]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available through the investor relations section of the Company’s website at www.regulusrx.com.

On September 11, 2020 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, reported that CEO, John Climaco, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on Wednesday, September 16th, 2020 at 9:30 AM EDT (Press release, CNS Pharmaceuticals, SEP 11, 2020, View Source;co-22nd-annual-global-investment-conference-301128132.html [SID1234565035]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 22nd Annual Global Investment Conference:

Date:

Wenesday, September 16th, 2020

Time:

9:30 AM EDT

Link:

View Source

A replay of the presentation will be available on the Company’s website for 90 days following the event. Members of management will hold 1-on-1 virtual investor meetings at the conference. Investors attending the conference virtually who are interested in meeting with Company management should contact their H.C Wainwright representatives.

On September 11, 2020 Veracyte, Inc. (Nasdaq: VCYT) reported the initiation of a European study that will utilize the Delphi methodology to generate consensus regarding the clinical utility of genomic tests in breast cancer treatment (Press release, Veracyte, SEP 11, 2020, View Source [SID1234565020]). Led by an independent scientific committee of breast cancer experts with input from 180 breast cancer clinicians practicing in 12 European countries, the PROCURE study will explore and achieve consensus on the evidence supporting the most frequently used breast cancer multigene signatures (i.e., genomic tests).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As we’ve continued to learn more about how genomics impact treatment response and outcomes in breast cancer patients, genomic tests have become an invaluable tool for physicians," said Giuseppe Curigliano, MD, PhD, Istituto Europeo di Oncologia, Milan, and the PROCURE study coordinator. "However, there is not yet any consensus in the breast cancer community regarding the utility and ideal application of available tests, and this significantly complicates decision making. I’m excited to lead this study, which will generate this consensus using real-world insights and experiences from leading clinicians across Europe."

The Delphi method is a survey technique and established methodology for facilitating consensus on complex issues. The process includes at least two rounds of a structured questionnaire containing items to which participants express their degree of agreement. Consensus is reached by grouping participants’ responses after each successive wave of questioning. The PROCURE study will be conducted by Adelphi Targis, a medical research, education and communication agency with extensive experience using the Delphi methodology, and guided by an independent scientific committee led by Dr. Curigliano.

Over approximately 12 months, the study will gather input from participants to:

Comprehensively evaluate the existing evidence supporting the use of breast cancer genomic tests and the added value that clinicians attribute to them.
Assess the current and optimized use of these tools in patients with differing clinical-pathological profiles.
Establish recommendations on their use in routine clinical practice.
Discuss future clinical applications and research opportunities to facilitate a precision medicine approach in breast cancer.
Applying the rigorous Delphi process, the PROCURE scientific committee will use published clinical evidence along with participants’ input to establish and publish consensus recommendations for the use of genomic tests in clinical practice.

"PROCURE will provide much-needed guidance to breast cancer clinicians and their patients, helping them fully access the benefits offered by genomic testing," said Bonnie Anderson, Veracyte’s chairman and chief executive officer. "We’re grateful for the opportunity to sponsor this important study and to demonstrate our commitment to the global breast cancer community."